RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances Epirubicin sensitivity of breast cancer cells

Molecular and Cellular Biochemistry

Volumn 308, Issue 1-2, 2008, Pages 161-168

  Sun, Ping ^a,b   Gao, Jie ^a   Liu, Yan Li ^a   Wei, Lu Wan ^a   Wu, Li Ping ^a   Liu, Zhi Yu ^a  

^a SHANDONG UNIVERSITY   (China)

^b MUDANJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Breastcancer; Epirubicin; Human lymphatic endothelial cells (HLECs); RNA interference (RNAi); Vascular endothelial growth factor C (VEGF C)

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EPIRUBICIN; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; VASCULOTROPIN C;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE SEQUENCE; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; NUCLEOTIDE SEQUENCE; POSTTRANSCRIPTIONAL GENE SILENCING; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; EPIRUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HUMANS; LYMPHANGIOGENESIS; LYMPHOID TISSUE; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 38649115326     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-007-9624-1     Document Type: Article

References (30)

1. Veronesi U, Boyle P, Goldhirsch A et al (2005) Breast Cancer. Lancet 365:1727-1741
2. Braun S, Vogl FD, Naume B et al (2005) A pooled analysis of bone marrow micro-metastasis in breast cancer. N Engl J Med 353:793-802
3. Rampaul RS, Miremad A, Pinder SE et al (2001) Pathological validation and significance of micrometastasis in sentinel nodes in primary breast cancer. Breast Cancer Res 3:113-116
4. Krishnan J, Kirkin V, Steffen A et al (2003) Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 63:713-722
5. Schoppmann SF, Birner P, Stöckl J et al (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161:947-956
6. Vlahakis NE, Young BA, Atakilit A et al (2005) The lymphangiogenesis vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J Biol Chem 280:4544-4552
7. Jeltsch M, Kaipainen A, Joukov V et al (1997) Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423-1425
8. Karpanen T, Egeblad M, Karkkainen M et al (2001) Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61:1786-1790
9. Shi X, Chen G, Xing H et al (2007) VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro. Oncol Rep 18:241-247
10. Ochi N, Matsuo Y, Sawai H et al (2007) Vascular endothelial growth factor-C secreted by pancreatic cancer cell line promotes lymphatic endothelial cell migration in an in vitro model of tumor lymphangiogenesis. Pancreas 34:444-451
11. Schoppmann SF, Fenzl A, Schindl M et al (2006) Hypoxia inducible factor-1alpha correlate with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 99:135-141
12. Dias S, Choy M, Alitalo K et al (2002) Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99:2179-2184
13. Li JF, Ou YT, Wang TF et al (2004) Preoperative chemotherapy of continuous infusion of 5-Fluorouracil, Epirubicin or Pirarubicin and cyclophosphamine in operable primary breast cancer. Chinese Journal of Cancer Res 16:197-202
14. Grishok A, Tabara H, Mello CC (2000) Genetic requirements for inheritance of RNAi in C. elegans. Science 287:2494-2497
15. Harborth J, Elbashir SM, Bechert K et al (2001) Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 114:4557-4565
16. Sui G, Soohoo C, Affar el B et al (2002) A DNA vector based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99:5515-5520
17. Yu JY, DeRuiter SL, Turner DL (2002) RNA interfering by expression of short interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 99:6047-6052
18. Bjorndahl M, Cao R, Nissen LJ et al (2005) Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 102:15593-15598
19. Okamoto K, Ocker M, Neureiter D et al (2007) Bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells. Cell Mol Med 11:349- 361
20. Pytowski B, Goldman J, Persaud K et al (2005) Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 97:14-21
21. HeY, Kozaki K, Karpanen T et al (2002) Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor-3 signaling. J Natl Cancer Inst 94:819-825
22. Miyagishi M, Hayashi M, Taira K (2003) Comparison of the suppression effects of antisense oligonucleotides and siRNA directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 13:1-7
23. Paddison PJ, Caudy AA, Hannon GJ (2002) Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 99:1443-1448
24. Mattila MM, Ruohola JK, Karpanen T et al (2002) VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 98:946-951
25. Ji RC (2006) Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev 25:677-694
26. Ji RC (2007) Lymphatic endothelial cells, inflammatory lymphangiogenesis, and prospective players. Curr Med Chem 14:2359-2368
27. Ejlertsen B, Hojris I, Hansen S et al (2003) Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: A pilot study performed by the Danish Breast Cancer Cooperative Group. Breast 12:42-50
28. Lindman H, Astrom G, Ahlgren J et al (2007) Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. Acta Oncol 46:165-171
29. Benimetskaya L, Lai JC, Khvorova A et al (2004) Relative Bcl-2 indepenence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Clin Cancer Res 10:8371-8379
30. Karl E, Warner K, Zeitlin B et al (2005) Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 65:5063-5069